Menu
GWAS Study

Genome-wide meta-analysis of myasthenia gravis uncovers new loci and provides insights into polygenic prediction.

Braun A, Shekhar S, Levey DF et al.

39537604 PubMed ID
GWAS Study Type
668368 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

BA
Braun A
SS
Shekhar S
LD
Levey DF
SP
Straub P
KJ
Kraft J
PG
Panagiotaropoulou GM
HK
Heilbron K
AS
Awasthi S
MH
Meleka Hanna R
HS
Hoffmann S
SM
Stein M
LS
Lehnerer S
MP
Mergenthaler P
EA
Elnahas AG
TA
Topaloudi A
KM
Koromina M
PT
Palviainen T
AB
Asbjornsdottir B
SH
Stefansson H
SA
Skuladóttir AT
JI
Jónsdóttir I
SK
Stefansson K
RK
Reis K
ET
Esko T
PA
Palotie A
LF
Leypoldt F
SM
Stein MB
FP
Fontanillas P
KJ
Kaprio J
GJ
Gelernter J
DL
Davis LK
PP
Paschou P
TM
Tannemaat MR
VJ
Verschuuren JJGM
KG
Kuhlenbäumer G
GP
Gregersen PK
HM
Huijbers MG
SF
Stascheit F
MA
Meisel A
RS
Ripke S
Chapter II

Abstract

Summary of the research findings

Myasthenia gravis (MG) is a rare autoantibody-mediated disease affecting the neuromuscular junction. We performed a genome-wide association study of 5708 MG cases and 432,028 controls of European ancestry and a replication study in 3989 cases and 226,643 controls provided by 23andMe Inc. We identified 12 independent genome-wide significant hits (P < 5e-8) across 11 loci. Subgroup analyses revealed two of these were associated with early-onset (at age <50) and four with late-onset MG (at age ≥ 50). Imputation of human leukocyte antigen alleles revealed inverse effect sizes for late- and early-onset, suggesting a potential modulatory influence on the time of disease manifestation. We assessed the performance of polygenic risk scores for MG, which significantly predicted disease status in an independent target cohort, explaining 4.21% of the phenotypic variation (P = 5.12e-9). With this work, we aim to enhance our understanding of the genetic architecture of MG.

5,708 European ancestry cases, 432,028 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

668368
Total Participants
GWAS
Study Type
Yes
Replicated
3,989 cases, 226,643 controls
Replication Participants
European
Ancestry
Greece, Netherlands, Sweden, U.S., Norway, Finland, Italy, U.K., France, Germany, Iceland, Estonia
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.